Compare XENE & RDNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XENE | RDNT |
|---|---|---|
| Founded | 1996 | 1985 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.8B |
| IPO Year | 2014 | 1996 |
| Metric | XENE | RDNT |
|---|---|---|
| Price | $65.42 | $61.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $68.55 | ★ $82.80 |
| AVG Volume (30 Days) | ★ 1.5M | 748.1K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $311,000.00 | ★ $1,616,630,000.00 |
| Revenue This Year | N/A | $22.78 |
| Revenue Next Year | $2,496.48 | $10.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 13.05 |
| 52 Week Low | $30.00 | $50.79 |
| 52 Week High | $72.66 | $85.84 |
| Indicator | XENE | RDNT |
|---|---|---|
| Relative Strength Index (RSI) | 57.04 | 51.97 |
| Support Level | $52.40 | $51.59 |
| Resistance Level | $72.66 | $63.48 |
| Average True Range (ATR) | 2.72 | 2.63 |
| MACD | -0.51 | -0.65 |
| Stochastic Oscillator | 39.18 | 33.56 |
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostic.